Neurology® Podcast

Dr. Sumanth Reddy and Dr. Jeffrey Gelfand, both neurologists at UCSF, dive into the intricate world of small vessel primary CNS vasculitis. They discuss the complex clinical features and the vital role of biopsy confirmation for accurate diagnosis. The doctors advocate for early use of cyclophosphamide over glucocorticoids to expedite remission. They also explore the challenges of defining remission and the importance of spinal fluid testing in monitoring disease activity, emphasizing collaborative treatment approaches for better patient outcomes.

Join Dr. Greg Cooper as he chats with Dr. David A. Wolk, a distinguished neurologist from the University of Pennsylvania, specializing in LATE. They delve into the nuances of limbic predominant age-related TDP-43 encephalopathy, highlighting its critical links to cognitive decline and Alzheimer's disease. The discussion covers the evolving recognition of LATE, challenges in accurate diagnosis, and the importance of advanced biomarkers like FDG PET imaging. Wolk's insights shed light on LATE's distinct clinical features and the urgency for better diagnostic tools.

Dr. Stacey Clardy talks with Dr. Elia Sechi about the importance of understanding lab test results, the performance characteristics of assays, and the real-world implications of false positives in myasthenia gravis testing. Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

Dr. Roy E. Strowd talks with Dr. Susannah Cornes about a teaching incentive initiative designed to support and reward faculty in academic neurology.  Read the related article in Neurology® Education.  Disclosures can be found at Neurology.org. 

Dr. Per Borghammer, a physician researcher from Aarhus University, dives into groundbreaking insights on Lewy body disease. He discusses the crucial distinction between brain-first and body-first subtypes, highlighting newly identified parasympathetic and sympathetic variations. Borghammer explores how these classifications impact symptom development, proving vital for precision medicine. He also addresses the challenges of diagnosing preclinical stages of Parkinson's, emphasizing the importance of analyzing non-brain tissues to improve early detection.

Dr. Stacey Clardy talks with Dr. Janis Miyasaki about her journey into neurology, the integration of palliative care into neurologic practice, and the critical importance of patient-centered care. Read more about the 2025 AAN President's Award.  Disclosures can be found at Neurology.org. 

Dr. Jessica Ailani talks with Dr. Kathleen Digre about the evolution of spontaneous intracranial hypotension (SIH) diagnosis and treatment over the past decade. Disclosures can be found at Neurology.org. 

Dr. Dan Ackerman talks with Dr. Trey Bateman about the significance of blood-based biomarkers in Alzheimer disease. Purchase Annual Meeting On Demand to get access to the recordings and the ability to claim CME through March 1, 2026.  Disclosures can be found at Neurology.org.   

The May 2025 recall features four previously posted episodes on myasthenia gravis. The first episode has Dr. Fredrik Piehl discussing rituximab for new-onset generalized MG. In the second episode, Dr. Vera Bril explores the potential use of immunoglobulin as a corticosteroid-sparing agent in MG patients. The third episode features Dr. Ali A. Habib discussing trends in hospital admissions and in-hospital mortality for adult MG patients. The series concludes with Dr. Jennifer Morganroth addressing the increase in thymectomy procedures post-MGTX trial, disparities in access to these surgeries among different demographic groups, and the rise of minimally invasive surgical techniques. Podcast links: Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis  Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis Hospitalizations and Mortality from MG Hospitalizations and Mortality From Myasthenia Gravis Trends and Disparities in the Utilization of Thymectomy for MG in the US Article links: Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis Hospitalizations and Mortality From Myasthenia Gravis Trends and Disparities in the Utilization of Thymectomy for Myasthenia Gravis in the United States Disclosures can be found at Neurology.org.

Dr. Greg Cooper talks with Dr. Joseph Therriault about the use of plasma biomarkers in diagnosing Alzheimer disease, emphasizing the importance of interpreting these biomarkers within the clinical context of the patient.  Read the related article in Nature. Disclosures can be found at Neurology.org.